Recent News

• 06.02.2026 - Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
• 05.28.2026 - Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.27.2026 - Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
• 05.13.2026 - Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
• 05.12.2026 - Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
• 05.07.2026 - Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
• 05.07.2026 - Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
• 05.04.2026 - Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

Recent Filings

• 05.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.20.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.12.2026 - EX-99.1 EX-99.1